![](/img/cover-not-exists.png)
Phase 2, open-label study of ceritinib in patients (pts) with advanced non-lung solid tumors and hematological malignancies characterized by genetic abnormalities in anaplastic lymphoma kinase (ALK) using a flexible adaptive design: ASCEND-10
Kiss, I., Rodón, J., Pulido, E. Grande, Rha, S.Y., Sathornsumetee, S., Hess, G., Eigendorff, E., Cesic, D., Sutradhar, S., Pramanik, B., Kim, T.M.Volume:
27
Language:
english
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdw368.53
Date:
October, 2016
File:
PDF, 41 KB
english, 2016